Skip to main content

Table 3 Clinicopathologic characteristics and oncological outcomes of 95 patients with stage 0-III rectal cancer undergoing robotic-assisted total mesorectal excision

From: Robotic-assisted total mesorectal excision with the single-docking technique for patients with rectal cancer

Preoperative clinical staging

 Tumor depth

  T1

2 (2.1%)

  T2

19 (20.0%)

  T3

61 (64.2%)

  T4

13 (13.7%)

 Lymph Node metastasis

  N0

38 (40.0%)

  N1

40 (42.1%)

  N2

17 (17.9%)

 AJCCa Stage (Clinical)

  I

14 (14.7%)

  II

24 (25.3%)

  III

57 (60.0%)

Postoperative pathological outcomes

 Histology

  Well differentiation

16 (16.9%)

  Moderate differentiation

76 (80.0%)

  Poor differentiation

3 (3.1%)

 Tumor size

  < 5 cm

85 (89.5%)

   ≥ 5 cm

10 (10.5%)

 Tumor size (cm, mean ± SD) (range)

2.46 ± 1.652 (0–8)

 Tumor depth

  T0

29 (30.5%)

  Tis

1 (1.0%)

  T1

14 (14.7%)

  T2

20 (21.1%)

  T3

28 (29.5%)

  T4

3 (3.2%)

 Lymph Node metastasis

  N0

73 (77.1%)

  N1

19 (19.8%)

  N2

3 (3.1%)

 AJCC Stage (Pathologic)

  0

27 (28.4%)

  I

27 (28.4%)

  II

19 (20.0%)

  III

22 (23.2%)

 Tumor Regression Grade (75 patients with preoperative CCRT)

  0

28 (37.3%)

  1

30 (40.0%)

  2

11 (14.7%)

  3

6 (8.0%)

 Harvested Lymph Node (median) (range)

9 (0–36)

 Harvested Apical Node (median) (range)

2 (0–15)

 Distance of distal resection margin (cm, median) (range)

2.30 (0.2–6.5)

 Distance of circumferential resection margin (cm, median) (range)

1.0 (0.2–3.5)

 Distal resection margin

  Free

94 (98.9%)

  Positive

1 (1.1%)

 Circumferential resection margin

  Free

93 (97.9%)

  Positive

2 (2.1%)

 Resection Degree of Primary tumor

  R0

92 (96.8%)

  R1

3 (3.2%)

 Oncological outcomes

 Follow-up periods (months, median) (range)

25.6 (6.6–52.2)

 R0 resection

91

  Locoregional recurrence

5 (5.5%)

  Distant metastasis

10 (11.0%)

   Liver + Lung

1 (1.1%)

   Lung

5 (5.5%)

   Liver

2 (2.2%)

   Chest Wall

1 (1.1%)

   Peritoneal carcinomatosis

1 (1.1%)

 R1 resection

3

  Local recurrence

1 (33.3%)

  Lung

1 (33.3%)

  Peritoneum

1 (33.3%)

  1. a AJCC American Joint Commission on Cancer